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Reduced dose of PTCy followed 
by adjuvant α‑galactosylceramide 
enhances GVL effect 
without sacrificing GVHD 
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Posttransplantation cyclophosphamide (PTCy) has become a popular option for haploidentical 
hematopoietic stem cell transplantation (HSCT). However, personalized methods to adjust immune 
intensity after PTCy for each patient’s condition have not been well studied. Here, we investigated 
the effects of reducing the dose of PTCy followed by α‑galactosylceramide (α‑GC), a ligand of iNKT 
cells, on the reciprocal balance between graft‑versus‑host disease (GVHD) and the graft‑versus‑
leukemia (GVL) effect. In a murine haploidentical HSCT model, insufficient GVHD prevention after 
reduced‑dose PTCy was efficiently compensated for by multiple administrations of α‑GC. The ligand 
treatment maintained the enhanced GVL effect after reduced‑dose PTCy. Phenotypic analyses 
revealed that donor‑derived B cells presented the ligand and induced preferential skewing to the 
NKT2 phenotype rather than the NKT1 phenotype, which was followed by the early recovery of all T 
cell subsets, especially  CD4+Foxp3+ regulatory T cells. These studies indicate that α‑GC administration 
soon after reduced‑dose PTCy restores GVHD‑preventing activity and maintains the GVL effect, 
which is enhanced by reducing the dose of PTCy. Our results provide important information for the 
development of a novel strategy to optimize PTCy‑based transplantation, particularly in patients with 
a potential relapse risk.
Abbreviations
PTCy  Posttransplantation cyclophosphamide
HSCT  Hematopoietic stem cell transplantation
α-GC  α-Galactosylceramide
GVHD  Graft-versus-host disease
GVL  Graft-versus-leukemia
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APCs  Antigen-presenting cells
IFN  Interferon
TNF  Tumor necrosis factor
IL  Interleukin
PLZF  Promyelocytic leukemia zinc finger
Th1  Type 1 helper T
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NKT1  Th1-biased NKT
Treg  Regulatory T
lipo α-GC  Liposome formulation containing α-GC
TCD  T cell-depleted
BM  Bone marrow
B6  C57BL/6 J
TBI  Total body irradiation
IVIS  In vivo imaging system
DCs  Dendritic cells
HSC  Host stem cell
CNIs  Calcineurin inhibitors
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with various hemato-
logical  malignancies1,2. In recent years, HLA-haploidentical HSCT has helped overcome the limitations associated 
with the donor source, and posttransplant cyclophosphamide (PTCy) is an effective GVHD prophylaxis in this 
 setting3. Studies exploring the mechanisms have shown that PTCy can reduce alloreactive T cells and induce 
functional impairment of surviving effector T cells while sparing regulatory T cells through the expression of 
aldehyde  dehydrogenase4–6.
Although many clinical studies have shown that PTCy-based haploidentical HSCT has clinical superiority 
in terms of low non relapse-related mortality, concerns have been raised regarding the possible reduction in the 
graft-versus-leukemia (GVL) effect and the increased relapse rate of hematological cancer, especially in patients 
with an unfavorable disease status at transplantation or those requiring reduced-intensity  conditioning7–13. In 
such cases, a full-dose of conditioning is often required to enhance the GVL effect and control tumors in patients, 
however, it may increase the risk of severe GVHD. Theoretically, PTCy dose reduction might generate GVL 
activity, however, reliable methods for recovering the weakened GVHD preventive activity after reduced-dose 
PTCy in patients receiving a full-dose of conditioning have not been well studied. Therefore, the development of 
an immunomodulatory strategy that can enhance the GVL effect while maintaining sufficient control of GVHD 
after PTCy-based HSCT is needed.
α-galactosylceramide (α-GC), a synthetic glycolipid originally isolated from the marine sponge Agelas mau-
ritianus, is a representative ligand of invariant natural killer T (iNKT)  cells14. α-GC is presented to iNKT cells 
by CD1d on antigen-presenting cells (APCs)15,16. Stimulated iNKT cells rapidly produce various cytokines, such 
as interferon (IFN)-γ, tumor necrosis factor (TNF), interleukin (IL)-4, IL-10 and IL-1317–19. In accordance with 
gene expression or cytokine profiling, it has been shown that iNKT cells express promyelocytic leukemia zinc 
finger (PLZF) and are generally divided into three phenotypes: type 1 helper T cell (Th1)-biased NKT (NKT1), 
NKT2, and NKT17, corresponding to Th1, Th2 and Th17 responses,  respectively20–24.
Previous murine studies have shown that stimulation of iNKT cells by α-GC can induce immune tolerance 
in solid organ transplantation and  HSCT25–29. In HSCT, α-GC stimulates host-type iNKT cells to produce large 
amounts of Th2 cytokines by a STAT6-dependent  mechanism27 and promotes regulatory T cell (Treg) expansion 
in vivo29. Subsequently, a liposome formulation containing α-GC (lipo α-GC) was developed to efficiently and 
safely prevent acute GVHD and graft rejection by B cell-biased antigen  presentation26,28,30–33. Based on these find-
ings, a phase II clinical trial was performed and demonstrated that the administration of lipo α-GC immediately 
after HSCT contributed to the prevention of acute GVHD and that this effect was dependent on Treg  expansion34.
In this study, we first examined whether PTCy dose reduction can enhance the GVL effect. We then examined 
whether lipo α-GC as an immune adjuvant can compensate for the reciprocal balance between the GVL effect 
and GVHD prevention after modulating the PTCy dose. This study aimed to demonstrate the possibility of a 
novel immune-modulatory strategy to optimize PTCy-based transplantation, particularly for patients with a 
potential relapse risk.
Results
PTCy ameliorates GVHD in a dose‑dependent manner. We first assessed the GVHD-preventing 
impact of PTCy on a haploidentical BMT model. Transplantation of 5 ×  106 T cell-depleted bone marrow (TCD-
BM) cells and 10 ×  106 splenocytes from donor C57BL/6 J (B6) mice into lethally irradiated recipient B6D2F1 
mice was carried out, followed by PTCy administration 3 days after BMT (Fig. 1A). We used 12 Gy of the total 
body irradiation (TBI) as a lethal irradiation in this experimental setting. A pilot experiment to identify the 
optimal dose of cyclophosphamide for PTCy showed that PTCy at a dose of 50 mg/kg significantly protected 
recipients from acute GVHD, while a dose of 100 mg/kg failed to do so (Fig. S1). Therefore, we decided to use 
50 mg/kg cyclophosphamide, defined as “Full PTCy”, to prevent GVHD effectively in our murine BMT model. 
Next, the impact of a half dose of cyclophosphamide, defined as “Reduced PTCy”, was tested in the same model. 
The overall survival rate of the transplanted cohorts was improved by full PTCy (red closed circle) but not the 
reduced PTCy (blue closed square) as compared to allogeneic control (black closed triangle) (Fig.  1B). The 
clinical GVHD score of the full PTCy cohort (red closed circle) was significantly lower than that of the reduced 
PTCy cohort (blue closed square) on days 14, 21, 28, 35 and 56 (Fig. 1C). These results indicate that the GVHD-
preventing effect is dependent on the PTCy-dose, and a reduced PTCy of 25 mg/kg in this model was not suf-
ficient to control GVHD compared to a full PTCy of 50 mg/kg.
Additional administration of lipo α‑GC could compensate for the insufficient GVHD preven‑
tion after reduced‑dose PTCy. To examine the effect of lipo α-GC on GVHD preventive activity in our 
experiment, we attempted a lipo α-GC treatment with or without PTCy after transplantation (Fig. 2a). Although 
3
Vol.:(0123456789)
Scientific Reports |        (2021) 11:13125  | https://doi.org/10.1038/s41598-021-92526-z
www.nature.com/scientificreports/
Figure 1.  GVHD is prevented by optimized treatment with PTCy. (A) Experimental scheme: 5 ×  106 TCD-BM 
cells and 10 ×  106 splenocytes from B6 donor mice were administered to lethally irradiated (12 Gy TBI) B6D2F1 
recipient mice. Cyclophosphamide or a control vehicle was administered on day 3 after BMT. (B) Overall 
survival rates of the vehicle (n = 14), reduced PTCy (n = 14) and full PTCy (n = 14) groups at serial time points. 
Data are representative of four independent experiments. P values were determined by the log-rank test and 
Holm’s adjustment for multiple comparisons. ns, not significant (P > 0.05). (C) Clinical scores of the vehicle 
(n = 14), reduced PTCy (25 mg/kg) (n = 14) and full PTCy (50 mg/kg) (n = 14) groups at serial time points. Data 
are representative of four independent experiments and expressed as the mean ± SEM. P values were determined 
by one-way ANOVA and Tukey’s adjustment for multiple comparisons (allogeneic: reduced PTCy vs allogeneic: 
full PTCy). *P < 0.05; **P < 0.01; ****P < 0.0001.
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Figure 2.  Lipo α-GC improves both the percent survival and the GVHD score impaired by reducing the dose of PTCy. (a) 
Experimental scheme: 5 ×  106 TCD-BM cells and 10 ×  106 splenocytes from B6 donor mice were administered to lethally 
irradiated (12 Gy TBI) B6D2F1 recipient mice. Cyclophosphamide or a control vehicle was administered on day 3, followed 
by lipo α-GC administration on days 3, 5 and 7 after BMT. (b) Overall survival rates of the vehicle (n = 14), reduced PTCy 
(n = 14), full PTCy (n = 14), lipo α-GC (n = 16), reduced PTCy plus lipo α-GC (n = 16) and full PTCy plus lipo α-GC (n = 14) 
groups at serial time points. Data are representative of four independent experiments. P values were determined by the 
log-rank test and Holm’s adjustment for multiple comparisons. ns, not significant (P > 0.05). (c) Clinical scores of the vehicle 
(n = 14), reduced PTCy (n = 14), full PTCy (n = 14), lipo α-GC (n = 16), reduced PTCy plus lipo α-GC (n = 16) and full PTCy 
plus lipo α-GC (n = 14) groups at serial time points. Data are representative of four independent experiments and expressed as 
the mean ± SEM. P values were determined by one-way ANOVA and Tukey’s adjustment for multiple comparisons (allogeneic: 
reduced PTCy vs allogeneic: reduced PTCy plus lipo α-GC). *P < 0.05.
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each lipo α-GC monotherapy (black open triangle) or reduced PTCy monotherapy (blue closed square) resulted 
in prolonged survival as compared to allogeneic control cohort without receiving any therapies (violet closed 
triangle), the effects were just limited (Fig. 2b). Interestingly, the combination therapy of reduced PTCy and lipo 
α-GC (black open square) remarkably improved the overall survival and GVHD clinical scores as compared to 
the monotherapy with reduced PTCy (blue closed square), suggesting that the reduced PTCy and lipo α-GC syn-
ergistically prevented GVHD (Fig. 2b,c). These results indicated that the additional administration of lipo α-GC 
could compensate for the insufficient GVHD prevention mediated by reduced-dose PTCy alone.
Full PTCy reduced the GVL effect, while administration of lipo α‑GC did not. Since post-trans-
plant relapse is one of the leading causes of death after transplantation as well as GVHD, it is critical that suf-
ficient GVL effect is ensured after the administration of each PTCy or lipo α-GC which may deeply affect donor 
effector T cell function. We therefore conducted the experiments to investigate whether the GVHD-preventing 
activity by PTCy or by lipo αGC could lead to the reduction of the GVL effect or not.
To evaluate the GVL activity, we set up tumor-bearing recipients by transferring luciferase-expressing P815 
cells (Fig. 3a). To minimize the relative impact of PTCy on the tumor and evaluate the GVL effect of the donor’s 
immunity, the tumor volume was carefully titrated and set to the maximum amount that does not cause acute 
death. As for dose of RT, we attempted to examine the GVL activity under the condition with TBI 12 Gy and 
10 Gy, as near settings as in Fig. 2; however, recipients after reduced-PTCy died within 50 days after transplant 
by GVHD and it was impossible to evaluate the GVL activity. We therefore used a lower TBI dose (8 Gy) which 
enabled to reduce the GVHD intensity and assess the tumor-related lethality over 100 days.
In the syngeneic settings, the survival rates were decreased in proportion to the onset of tumor-specific clini-
cal features such as leg paralysis or macroscopic tumor infiltration into the liver and spleen at approximately 3 
or 4 weeks after BMT (black and gray closed circles) (Fig. 3b). Allogeneic cohorts without PTCy (violet closed 
triangle) or with full PTCy (red closed circle) significantly prolonged the survival compared to syngeneic cohorts 
(black and gray closed circles), however, a major proportion of recipients died until 12 weeks. In contrast, alloge-
neic cohort with reduced PTCy (blue closed square) remarkably improved overall survival more than full PTCy 
(red closed circle). The addition of lipo α-GC treatment after reduced or full PTCy (black open square and black 
open circle, respectively) resulted in the comparable survival as compared to the corresponding cohorts receiv-
ing PTCy alone (blue closed square and red closed circle, respectively) (Fig. 3b). The clinical GVHD scores in all 
eight cohorts were maintained at low levels and did not reach fatal GVHD severity throughout the experimental 
period (Fig. 3c). Also, there was no difference in GVHD severity among the 8 cohorts. This data suggest that 
the main cause of death in this experimental setting was tumor progression rather than GVHD. Quantitative 
analysis using an in vivo imaging system (IVIS) enabled monitoring of the progression of the inoculated lucif-
erase-expressing P815 cells in each mouse. As early as day 10, tumor signaling was detected in some recipients 
in the cohorts without PTCy, but not in the cohorts with PTCy, suggesting that PTCy itself has a certain impact 
on tumor control (Fig. 3d,S2). The percentage of positive tumor signal over time was clearly suppressed in the 
“Reduced PTCy” cohort (blue closed square) compared to the “Full PTCy” cohort (red closed circle) (Fig. 3d,e).
These results suggested that full PTCy could reduce the GVL effect resulting in the tumor-related mortality 
in recipients with a high tumor burden. In contrast, the additional administration of lipo α-GC appeared not 
to affect the GVL activity.
Lipo α‑GC administered after PTCy was delivered to B cells and macrophages rather than den‑
dritic cells. To identify which APC incorporated lipo α-GC administered after PTCy, we used a rhodamine-
labeled lipo α-GC. In our previous report, lipo α-GC preferentially accumulated in splenic marginal zone B 
cells in normal mice within 2  h after intravenous  injection32. We confirmed whether the target cells of lipo 
α-GC in normal mice were the same as those in the murine haploidentical BMT model. Lethally irradiated 
mice were intravenously injected with rhodamine-labeled lipo α-GC immediately after BMT, and their spleens 
were extracted 2 h after the injection (middle, in Fig. 4a). Splenic B cells, dendritic cells (DCs) or macrophages 
incorporating lipo α-GC were defined as  B220+CD3−,  B220−CD3−CD11c+ or  CD19−F4/80+CD11b+ cells in the 
rhodamine-positive gate of flow cytometric analysis, respectively (Fig. 4b). In contrast, cells not incorporating 
lipo α-GC were defined by the same gating in the rhodamine-negative gate (Fig. 4c).
In the non-PTCy conventional BMT model, rhodamine-positive cells mostly corresponded to host-derived 
B cells rather than DCs, but not to the donor graft-derived APC (Fig. 4d). Conversely, in the case of lipo α-GC 
treatment after PTCy, rhodamine-positive cells were mainly composed of graft-derived B cells and host stem 
cell (HSC)-derived macrophages (Fig. 4e). These results suggest that lipo α-GC is present in graft-derived B cells 
and stem cell-derived macrophages rather than DCs in the PTCy-based haploidentical transplant setting. We 
also checked the composition of APCs in the rhodamine-negative cells in non-PTCy conventional (Fig. 4f) and 
PTCy (Fig. 4g) BMT models, respectively. The comparison between Fig. 4e,g indicates that the percentage of 
the graft-derived subset in rhodamine-positive cells is relatively higher than that in rhodamine-negative cells.
Splenic T cells have a good potential to deliver lipo α‑GC after BMT. In addition to B cells, mac-
rophages, and DCs, CD1d is universally expressed in various cells and tissues. Therefore, we examined whether 
splenic T cells incorporated lipo α-GC after PTCy. Splenic T cells were analyzed on day 7 after murine BMT 
with reduced PTCy as shown in Fig. 4a. Rhodamine positive fraction involved  CD3+ cells, suggesting that some 
population of  CD3+ T cells can uptake lipo α-GC (Fig. 5a). A major part of Rhodamine positive T cells was donor 
graft-derived, and the absolute number was greater than that of Rhodamine positive APCs. This suggests that 
both B cells and T cells play an important role in delivering lipo α-GC after BMT.
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Profile of iNKT cell subsets skewed toward the Th2 phenotype after PTCy with lipo α‑GC 
treatment. We wondered whether the unique profile of the APCs incorporating lipo α-GC influences the 
proportion of each phenotype of iNKT cells. Splenocytes were prepared immediately after the third injection 
of lipo α-GC into the model mice (Fig. 6a). NKT1, NKT2 and NKT17 cells were defined as  PLZFlowRORγt−, 
 PLZFhighRORγt− and  PLZFintRORγt+ cells, respectively, in the iNKT cell population (Fig. 6b). The analysis of the 
chimerism of splenic iNKT cells showed that the donor/host cell ratio was significantly higher in the mice treated 
with PTCy and lipo α-GC, while the ratio in those receiving PTCy monotherapy was mostly equal (Fig. 6c). 
Additionally, a flow cytometric analysis showed that the proportion of cells with the NKT2 phenotype was 
remarkably increased after PTCy with lipo α-GC treatment, but not after PTCy monotherapy or non-treatment; 
however, the proportion of cells in the NKT1 subset was comparable among all treatments (Fig. 6d,e). The pro-
portion of NKT17 cells after PTCy monotherapy was significantly higher than those following other treatments, 
although the absolute number remains very low (Fig. 6f), suggesting that the expansion of NKT2-phenotype 
cells by PTCy with lipo α-GC treatment could inhibit the expansion of NKT17-phenotype cells induced by PTCy 
alone.
Lipo α‑GC enhances the expansion of donor graft‑derived Tregs. We then examined the impact 
of lipo α-GC on Tregs in our PTCy-based transplantation model (Fig.  7a). Each subset of T cells and their 
origin were defined as shown in the upper and lower panels of Fig. 7b, respectively. On day 14 after BMT, flow 
cytometric analysis of mesenteric lymph node (mLN) cells and splenocytes showed that PTCy with lipo α-GC 
induced significantly higher percentages of Tregs (P < 0.05) than the control vehicle or PTCy alone (Fig. 7c,S3a). 
The combined PTCy and lipo α-GC also increased  CD8+ T cells, but the ratio of Treg and  CD8+ T cells in this 
treatment group was higher than that in the other groups, suggesting that Treg increased predominantly and 
contributed to immune stability (Fig. S4).
On day 14, the majority of Tregs were derived from the donor graft (Fig. 7f). Analysis on day 28 showed that 
PTCy appeared to promote the emergence of donor stem cell-derived T cells including Tregs (Fig. 7g,h), and 
Treg levels in PTCy with lipo α-GC were maintained as compared with other groups (Fig. 7d,S3b). These results 
indicated that PTCy with lipo α-GC treatment could induce the expansion of donor graft-derived Tregs early 
after BMT, consequentially followed by the early emergence of donor stem cell-derived Tregs.
Discussion
It is clinically desirable that both GVHD prevention and GVL activation are achieved after HSCT, particularly 
in the setting of PTCy-based haploidentical transplantation in patients with a potential relapse risk. Although 
PTCy dose reduction might be assumed to generate GVL activity, it is not applicable in human clinical treatment 
due to unavailable reliable methods for recovery of the GVHD-preventing activity weakened by reducing the 
dose of PTCy. In our murine haploidentical transplantation model, we showed that lipo-α-GC could induce the 
regulatory functions of iNKT cells and perform a complementary role in preventing GVHD, combined with a 
reduced-dose PTCy. We also demonstrated that lipo α-GC could maintain a powerful GVL effect generated by 
reduced-dose PTCy.
We optimized a murine model of PTCy-based transplantation in a haploidentical setting to properly evalu-
ate the effect of lipo α-GC on PTCy. In this transplant setting, 50 mg/kg of PTCy was sufficient to prevent acute 
GVHD (Fig. 1B,C). PTCy at a dose of 100 mg/kg resulted in worse survival than 50 mg/kg of PTCy, suggesting 
that this dose might induce lethal side effects, such as cardiomyopathy (Fig. S1). We defined 50 mg/kg of PTCy 
as full PTCy as this was a safe dose that avoids drug-induced lethal side effects and effective in suppressing acute 
GVHD.
A previous murine study examining the biological effects of two doses of PTCy (22 mg/kg and 66 mg/kg) 
demonstrated that PTCy diminished alloreactive proliferating T cell numbers in a dose-dependent  manner35. In 
our study, a reduced PTCy, defined as a dose of 25 mg/kg, has insufficient GVHD prevention, and most recipients 
failed to survive to day 50. Meanwhile, a full PTCy efficiently prevented GVHD and resulted in survival rates 
Figure 3.  Full PTCy reduced the GVL effect, while administration of lipo α-GC did not. (a) Experimental 
scheme: 5 ×  106 TCD-BM cells and 10 ×  106 splenocytes from B6 donor mice were administered to sublethally 
irradiated (8 Gy TBI) B6D2F1 recipient mice, and 5 ×  105 luciferase-expressing P815 cells were also 
administered. Cyclophosphamide or a control vehicle was administered on day 3, followed by lipo α-GC 
administration on days 3, 5, and 7 after BMT. (b,c) Overall survival rates and clinical scores of the syngeneic: 
full PTCy (n = 6) or full PTCy plus lipo α-GC (n = 6) and allogeneic: vehicle (n = 11), lipo α-GC (n = 11), reduced 
PTCy (n = 11), full PTCy (n = 11), reduced PTCy plus lipo α-GC (n = 11) or full PTCy plus lipo α-GC (n = 11) 
groups at serial time points. Data are representative of two independent experiments. P values were determined 
by the log-rank test and Holm’s adjustment for multiple comparisons. (d) IVIS study of the syngeneic: full PTCy 
(n = 3) or full PTCy plus lipo α-GC (n = 3) and allogeneic: reduced PTCy (n = 6), full PTCy (n = 6), reduced 
PTCy plus lipo α-GC (n = 6) or full PTCy plus lipo α-GC (n = 6) groups at serial time points. (e) The percentage 
of positive tumor signal over time in syngeneic group (n = 6), allogeneic with full PTCy (n = 12) and allogeneic 
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comparable to syngeneic controls (Fig. 1B,C). These results indicate that our optimized BMT model is suitable 
for monitoring PTCy dose-dependent effects on GVHD prevention and overall survival prolongation.
The impact of α-GC on GVHD suppression by iNKT-mediated Treg expansion has been reported in murine 
models and clinical  studies25,26,34. Similar to these studies, our current study also showed that lipo α-GC mono-
therapy prolonged overall survival (Fig. 2a). However, the effect of α-GC has not been evaluated in a PTCy-based 
HSCT setting. Our data showed that lipo α-GC synergistically operated to recover the lost preventive activity 
against GVHD caused by reducing the PTCy dosage (Fig. 2b,c).
We then evaluated the GVL effect after PTCy using luciferase-expressing P815 tumor cells with a modified 
TBI (Fig. 2,3). Results showed that both full and reduced PTCy prevented tumor signals at day 10, but thereaf-
ter, significantly prolonged survival was observed in the reduced PTCy cohort than the full PTCy cohort. This 
indicates that although high-dose PTCy can provide tumor control immediately after transplantation, GVL 
attenuation by PTCy can have a substantial impact, and reducing the dose of PTCy can strengthen the GVL effect.
Notably, GVL after PTCy was not affected by lipo α-GC treatment (Fig. 3b). This is consistent with a previ-
ous study using a non-PTCy BMT model, which demonstrated that a single injection of lipo α-GC immediately 
after BMT in a P815 cell-inoculated murine acute GVHD model resulted in prolonged survival in recipient mice 
without loss of GVL  activity26.
As shown above, we set two different experimental settings in this study; one is to assess GVHD (TBI 12 Gy; 
Fig. 1,2), and the other is to assess GVL effect (TBI 8 Gy; Fig. 3,S2). Since the assessment of the long-term GVL 
effect was not possible due to the early GVHD-related mortality in the setting of lethal TBI (12 Gy), we used 
another setting with sublethal TBI (8 Gy) to evaluate the GVL effect. In this setting, GVHD was mild, and recipi-
ents could survive as long as the tumor was controlled by the GVL activity (Fig. 3c). It is difficult to accurately 
evaluate the GVL effect in the current murine HSCT model with lethal TBI as GVHD-related death can occur. 
This is an important limitation in translating basic findings to clinical situations and should be resolved in the 
future.
Our data demonstrated that lipo α-GC did not reduce the GVL activity in the setting with sublethal TBI 
(Fig. 3). It is true that the effect of lipo α-GC on GVL in the setting of lethal TBI was not evaluated in this study, 
however, we consider that it would be just limited because the GVL activity should be more enhanced after lethal 
TBI as compared to sublethal TBI. A previous murine study demonstrated that higher TBI is better to control 
P815 tumors when compared to that with reduced TBI by using the same system as our current study (B6 into 
B6D2F1)36. Consistent with this basic experiment, many clinical studies have already clarified that a higher dose 
of conditioning contributes to control tumors as compared to a lower  dose37,38. These previous findings suggest 
that the negative effect of lipo α-GC on the GVL activity could be further diminished or offset in the setting of 
lethal TBI. This is a very important point and should be carefully verified in future clinical trials.
To detect the main cells that present lipo α-GC, a rhodamine uptake assay was performed. Analysis following 
a single injection of lipo α-GC after BMT without PTCy showed that the splenic target cells incorporating lipo 
α-GC were mostly B cells derived from recipient mice. Meanwhile, the analysis following multiple injections after 
PTCy found that the target cells were B cells derived from the donor graft and macrophages from the reconsti-
tuted HSC population (Fig. 4d,e). Sonoda et al. reported that splenic marginal zone B cells promoted NKT cell-
dependent  tolerance39. In contrast, Arora et al. reported that various glycolipid antigens were presented mainly 
by DCs, not by B cells, and whether iNKT cells develop Th1- or Th2-response by lipo α-GC was determined 
by changes in the surface markers of DCs, consisting of various costimulatory and coinhibitory  molecules40. 
Figure 4.  APCs presenting lipo α-GC vary by phase after BMT. (a) 5 ×  106 TCD-BM cells from B6 
(H-2KbCD45.2 +) donor mice and 5 ×  106 splenocytes from Ly5.1-B6 (H-2KbCD45.1 +) donor mice were 
administered into lethally irradiated B6D2F1 (H-2 Kb/dCD45.2 +) recipient mice. In non-PTCy group, 
rhodamine-labeled lipo α-GC was administered within 30 min after transplantation. Two hours after 
the administration, splenocytes were collected from donor. In PTCy group, reduced dose of 25 mg/kg 
cyclophosphamide was administered intraperitoneally into recipient mice on day3. Lipo α-GC was administered 
intravenously on day 3, 5. On day 7, rhodamine-labeled lipo α-GC was administered. Two hours after the 
administration, splenocytes were collected from donor. Rhodamine uptake by APCs was assessed using flow 
cytometric analysis. (b,c) Representative data of flow cytometric analysis regarding Rhodamine positive or 
negative APCs are shown. Each gated cells were divided into B cells (CD3-B220 +), dendritic cells (CD3-
CD11chigh) and macrophages (CD19-F4/80highCD11bhigh). And, their chimeras are evaluated as host 
(H2Kd + CD45.1-) derived or donor graft (H2Kd-CD45.1-) derived or donor stem cell (H2Kd-CD45.1 +) 
derived, respectively. (d) In non-PTCy group, APCs taking in lipo α-GC and their chimeras on day 0 
immediately after BMT are revealed by flow cytometric analysis (n = 6). (e) In PTCy group, APCs taking in lipo 
α-GC and their chimeras on day7 after BMT are revealed, by flow cytometric analysis (n = 6). (f) In non-PTCy 
group, APCs not taking in lipo α-GC and their chimeras on day 0 immediately after BMT are revealed by flow 
cytometric analysis (n = 6). (g) In PTCy group, APCs not taking in lipo α-GC and their chimeras on day7 after 
BMT are revealed, by flow cytometric analysis (n = 6). Data are expressed as means ± SEM. P values by one-way 
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Figure 5.  Splenic T cells uptake lipo α-GC after BMT. Splenic T cells were analyzed on day 7 after 
murine BMT with reduced PTCy as shown in Fig. 4a. (a) Representative data of flow cytometric analysis 
regarding Rhodamine positive or negative CD3 + T cells are shown. Their chimeras are evaluated as host 
(H2Kd + CD45.1-) derived or donor graft (H2Kd-CD45.1-) derived or donor stem cell (H2Kd-CD45.1 +) 
derived, respectively. (b) APCs taking in lipo α-GC and their chimeras on day7 after BMT are revealed, by 
flow cytometric analysis (n = 6). (c) APCs not taking in lipo α-GC and their chimeras on day7 after BMT are 
revealed, by flow cytometric analysis (n = 6).
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Bezbradica et al. showed that B cells presenting α-GC preferentially induced IL-4 rather than IFN-γ production 
by NKT  cells41. Bai et al. demonstrated that compared with DCs, B cells stimulated iNKT cells more effectively 
when loaded with Th2-biased ligands than when loaded with conventional α-GC and induced relatively more 
IL-4 than IFN-γ  expression42. In our previous study, we administered lipo α-GC to mice and sorted the B cells. 
The sorted B cells were co-cultured with iNKT cells in vitro, and IL-10 production was induced without induc-
ing IFN-γ  production32. Results from the in vitro experiment suggested that iNKT cells can be promoted into 
NKT2-shift by stimulating with B cells that incorporated lipo α-GC. In a posttransplant environment, we believe 
that DCs are easily stimulated and activated by inflammatory cytokines and mediate Th1 skewing of NKT cells; 
therefore, B cell acquisition and presentation of α-GC is theoretically advantageous with respect to Th2 skewing 
of NKT cells.
Interestingly, some  CD3+ T cell populations also showed rhodamine-positive cells (Fig. 5a,b). Previous reports 
have demonstrated that CD1d is also expressed in T  cells43. Furthermore, a recent study analyzed the function 
of CD1d expressed on T cells and concluded that CD1d-expressing  CD8+ T cells present antigens to iNKT cells, 
producing IFN-γ, resulting in an enhanced antitumor  effect44. In our data, α-GC administration tended to pro-
long survival in the cohorts without PTCy (Fig. 3,S2), suggesting that donor-derived CTLs directly incorporating 
α-GC might exert an anti-tumor effect.
The function of the macrophages incorporating lipo α-GC remains unclear. It has been shown that mac-
rophages promote IL-4 production by iNKT cells when cultured in vitro with Th2-biased  ligands42. Other studies 
have reported that macrophages play critical roles in the distribution and migration of iNKT cells in vivo45,46. 
Thus, the HSC-derived macrophages incorporating lipo α-GC may have had some impact on iNKT homeostasis 
in our transplantation experiments. However, further studies are required to clarify the detailed functions of 
macrophages.
Flow cytometry analysis further subdivided NKT cells into NKT1, NKT2, and NKT17 cells according to the 
expression pattern of PLZF and RORγt (Fig. 6). Results showed that iNKT cells skewed toward the Th2 phenotype 
by PTCy with lipo α-GC treatment, indicating the impact of lipo α-GC on the phenotypic plasticity of iNKT 
cells in the posttransplant peripheral inflammatory environment (Fig. 6b). We previously demonstrated that 
host-derived iNKT cells and IL-4 production are required for the suppression of GVHD by α-GC27,29,47. In other 
studies, adoptive transfer of donor-type iNKT cells ameliorated GVHD via donor-derived Treg  expansion48,49. 
Moreover, it has been demonstrated that even third-party iNKT cells prevent GVHD via early expansion of Tregs, 
even though these iNKT cells are rejected shortly after  administration50. Our data on NKT2 skewing are in line 
with the data demonstrating B cell acquisition of α-GC, followed by the promotion of Treg expansion (Figs. 4, 6, 
and 7). Recent studies have identified NK-like-NKT1-related genes that can be distinguished from conventional 
NKT1-related genes in cytokine profile  differencies21,51. Although subtypes of NKT1 cells have different roles in 
GVHD and the GVL effect remains unclear, excessive proinflammatory cytokine production by NK-like cells 
presumably deteriorates GVHD. Unfortunately, T-bet staining was unstable under severe cytopenia and could not 
be used for the definition of NKT1 subset in this study. To further delineate NKT subsets after BMT, it is needed 
to overcome the technical issue in flow cytometry. Also, the comprehensive gene analysis using a next-generation 
sequencer may help to widely explore the genes that can characterize the effect and function of NKT subsets.
In our analysis of T cell reconstitution after PTCy with lipo α-GC, lipo α-GC administration was involved in 
more enhanced early recovery of both  CD4+ and  CD8+ T cell subsets than PTCy alone (Fig. 7c). In particular, 
Treg recovery was remarkably promoted. Donor graft-derived Tregs in the early phase after PTCy with lipo α-GC 
treatment might preserve the effect on the late phase by subsequently inducing donor stem cell-derived Tregs. 
In terms of combination therapy, it is important to determine which immunosuppressive therapy is appropriate 
to combine with α-GC therapy. Previous studies have shown that donor-derived Tregs are indispensable for the 
suppression of GVHD by a single treatment with PTCy or α-GC after  HSCT26,49,52. Our findings suggest that 
PTCy and α-GC function coordinately to increase donor-derived Treg numbers to induce tolerance. Although 
calcineurin inhibitors (CNIs) are widely used for GVHD prophylaxis, they have been shown to inhibit Tregs 
as well as alloreactive T  cells53. To produce a synergistic effect with α-GC on Treg expansion, PTCy might be 
preferable to  CNIs52.
In considering clinical applications, some differences in NKT cells between humans and mice must be 
acknowledged. In particular, the NKT cell population in mice is relatively large, and the number of human 
NKT cells is low. Therefore, the effect of NKT cells in human clinical transplantation may be relatively small 
compared to that in mouse.
To our knowledge, this is the first study to evaluate the efficacy of reduced-dose PTCy on the GVL effect in 
a murine PTCy-treated transplantation model. Our experiments clearly demonstrate that reducing the dose of 
PTCy can provide a promising strategy that enhances the GVL effect in this transplant setting. Our data may 
support clinical observations from a clinical trial which showed that reducing the dose of PTCy could result 
in prolonged survival among patients with severely high-risk  diseases54. However, in the clinical trial, severe 
GVHD was also observed after reduced-dose PTCy, which counterbalanced the clinical merit of potentially 
enhancing the GVL effect. Our trials focusing on iNKT activation by multiple administrations of lipo α-GC 
as an immune adjuvant may establish a novel strategy to resolve the insufficient GVHD suppression mediated 
by reduced-dose PTCy and maintain a favorable balance between GVHD suppression and GVL enhancement. 
Considering the increasing clinical use of PTCy-based transplantation, the addition of a combination therapy 
should be considered to optimize this transplantation approach, promote restoration tolerance, and eradicate 
the disease in patients after HSCT.
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Methods
Ethical statement. The study protocols were reviewed and approved by the Animal Care and Use Com-
mittee, Okayama University Advanced Science Research Center (protocol number: OKU-2017070 and OKU-
2018489). All experiments were performed in accordance with the study protocols. The study was carried out in 
compliance with the ARRIVE guidelines.
Mice. C57BL/6 J (H-2KbCD45.2+) mice and B6D2F1 (H-2  Kb/dCD45.2+) mice were purchased from Japan 
SLC (Shizuoka, Japan). C57BL/6-Ly5.1 (Ly5.1-B6, H-2KbCD45.1+) mice were purchased from RIKEN BRC 
(Tsukuba, Japan). In all experiments, 8- to 12-week-old female mice were used and maintained under specific 
pathogen-free conditions.
Experimental transplantation. TCD-BM cells were obtained using CD90.2 microbeads and an Auto 
MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany). B6D2F1 recipient mice received lethal 12 Gy TBI 
that was split into 2 doses at 6-h intervals to minimize gastrointestinal toxicities. On day 0, the recipient mice 
were injected intravenously with 5 ×  106 TCD-BM cells and 10 ×  106 splenocytes from B6 mice.
For assessment of the GVL effect, B6D2F1 recipient mice received sublethal 8 Gy TBI split into 2 doses. 
The recipient mice were transplanted as above, and 5 ×  105 luciferase-transduced P815 cells were injected 
intravenously.
Treatment with PTCy and lipo α‑GC. Cyclophosphamide was purchased from Sigma-Aldrich Japan 
(Tokyo, Japan). Ligands for iNKT cells, lipo α-GC (RGI-2001), were provided by REGiMMUNE Corp (Tokyo, 
Japan). Cyclophosphamide at a dose of 25 or 50 mg/kg was administered intraperitoneally into B6D2F1 recipient 
mice on day 3. Lipo α-GC at a dose of 1 μg/kg was intravenously administered on days 3, 5, and 7.
Assessment of GVHD and the GVL effect. Survival after transplantation was monitored daily, and signs 
of clinical GVHD were assessed weekly by evaluating changes in weight, posture, activity, fur texture, and skin 
integrity, as previously  described55. In a GVL model, death caused by leukemia was diagnosed by identifying 
hepatosplenomegaly, macroscopic tumor nodules in the liver or spleen, or hind-leg paralysis. Death caused by 
GVHD was identified by the absence of leukemia and the presence of clinical signs of GVHD. Tumor progres-
sion was also evaluated by bioluminescence imaging assay as shown in Supplemental Method.
Flow cytometric analysis. Single-cell suspensions of splenocytes or mLN cells were incubated with anti-
Fc receptor blocking antibodies and stained for surface markers with appropriate monoclonal antibodies (mAbs) 
for 30 min at 4 °C. To detect iNKT cells, cells were stained with R-PE-conjugated CD1d tetramers preloaded 
with α-GC, which were purchased from ProImmune (Oxford, England, UK). For intracellular staining, dead 
cells were first excluded with the Fixable Viability Dye (eBioscience), and cells were processed with the Foxp3 
Transcription Factor Staining Buffer Set (eBioscience) according to the manufacturer’s protocol. Finally, the cells 
were stained for intracellular markers with appropriate mAbs. Samples were acquired with the MACS Quant 
Analyzer (Miltenyi Biotec), and data were analyzed with FlowJo software (Tree Star, Ashland, OR). The mAbs 
used in this study are shown in supplemental information.
Statistical analysis. The Mann–Whitney U test and chi-square test were used to assess statistical signifi-
cance between two groups, and one-way ANOVA was used to compare more than two groups. Tukey’s adjust-
ment was used for multiple comparisons. The Kaplan–Meier method was used to obtain survival probabilities, 
and the log-rank test was applied to compare survival curves. Holm’s adjustment was used for multiple compari-
sons. P values < 0.05 were defined as statistically significant.
Figure 6.  Th2-phenotype iNKT cells are expanded by “Reduced PTCy” with lipo α-GC. (a) Experimental 
scheme: 5 ×  106 TCD-BM cells from B6 (H-2KbCD45.2+) donor mice and 10 ×  106 splenocytes from Ly5.1-B6 
(H-2KbCD45.1+) donor mice were administered to lethally irradiated B6D2F1 (H-2  Kb/dCD45.2+) recipient 
mice. A reduced dose of 25 mg/kg cyclophosphamide or control vehicle was administered on day 3, followed 
by lipo α-GC administration on days 3, 5, and 7 after BMT. On day 7 after BMT, the phenotypes of iNKT cells 
(live,  CD19−α-GC-loaded CD1d  tetramer+TCRβ+) were analyzed as follows: NKT1  (PLZFlowRORγt−), NKT2 
 (PLZFhighRORγt−), and NKT17  (PLZFintRORγt−). (b) Representative data from a flow cytometric analysis 
showing iNKT cells, their phenotypes and chimeras in the vehicle (n = 5), reduced PTCy (n = 5) and lipo α-GC 
plus reduced PTCy (n = 5) groups. (c) Chimerism of the iNKT cells in the vehicle (n = 5), reduced PTCy (n = 5) 
and lipo α-GC plus reduced PTCy (n = 5) groups. (d,e,f) Percentage of cells with each phenotype among the 
iNKT cells in the vehicle (n = 5), reduced PTCy (n = 5) and lipo α-GC plus reduced PTCy (n = 5) groups. P values 
were determined by one-way ANOVA and Tukey’s adjustment for multiple comparisons. *P < 0.05; **P < 0.01; 
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